Day 4 Program

Poster Spotlight 12: GLP-1

Day 4: December 11, 2026

7:00 AM–8:30 AM CST

Hemisfair 3

Session Details

Moderator

Arun Banu, The University of Texas MD Anderson, Houston, TX

PS12-1

GLP-1 Receptor Agonists and Overall Survival in Breast Cancer: A Systematic Review and Meta-Analysis

Kesar Prajapati, Metropolitan Hospital Center, New York, NY

PS12-2

GLP-1 Targeting Agents Impair Chemoimmunotherapy Response in Triple-Negative Breast Cancer through Tumor-Intrinsic and Microenvironment Mechanisms

Bethania Santos, University of Texas Southwestern Medical Center, Dallas, TX

PS12-3

GLP-1 Receptor Agonist Exposure and Clinical Outcomes in Triple-Negative Breast Cancer Treated with Pembrolizumab-Based Neoadjuvant Therapy: A Propensity Score-Matched Analysis

Grace Gorecki, Allegheny Health Network, Pittsburgh, PA

PS12-4

Fasting-mimicking diet plus neoadjuvant chemotherapy in early TNBC: 5-year survival outcomes and transcriptomic predictors of relapse from the BREAKFAST trial

Francesca Ligorio, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy

PS12-5

Concurrent GLP-1 receptor agonist use and outcomes with capivasertib in metastatic hormone receptor-positive, HER2-negative breast cancer

Zunairah Shah, Roswell park Comprehensive Cancer Center, Buffalo, NY

PS12-6

Impact of GLP-1 on Breast Cancer Care and Outcomes

Sherry Shen, Memorial Sloan Kettering Cancer Center, New York, NY

PS12-7

Glp-1 agonist use and contralateral breast cancer risk

Raissa Kentsa, The University of Texas MD Anderson Cancer Center, Houston, TX

PS12-8

Glucagon-like peptide-1 receptor agonists and incident breast cancer in women: a systematic review and meta-analysis contrasting real-world and randomized evidence.

Angela Theresa Zuffo Yabrude, Universidade Regional de Blumenau, Blumenau, Brazil

PS12-9

Change in Benign Breast Tissue Transcriptomics and other Biomarkers after 6 months of Tirzepatide in Women at High Risk for Development of Breast Cancer

Carol J Fabian, University of Kansas Medical Center, Kansas City, KS

PS12-10

Time-to-event analysis associates GLP-1 use with lower breast cancer incidence and weight loss identifies a lower-risk subgroup

Elizabeth S. McDonald, University of Pennsylvania, Philadelphia, PA

PS12-11

Tirzepatide Improves Metabolic Health and Decreases Mammary Tumor Susceptibility in High-Fat Diet-Fed Wild-Type and Brca1<sup>+/-</sup> Mice

Sailesh Palikhe, University of Kansas Medical Center, Kansas City, KS

PS12-12

Can we prevent breast cancer with GLP-1?

Claudine Isaacs